Academic Journal
Q1Statistics in Biopharmaceutical Research
About Statistics in Biopharmaceutical Research
Statistics in Biopharmaceutical Research is a scholarly journal published by Taylor and Francis Ltd.. SCImago 2025 lists it in Q1, with an SJR of 0.874 and H-index of 29.
Coverage: 2011-2026. Research categories: Pharmaceutical Science (Q1); Statistics and Probability (Q1).
Verified field sources
- Journal Impact Factor: 1.6 — Official source; checked 2026-10-03. Publisher-reported Journal Impact Factor and year from Taylor & Francis About this journal information.
- Impact Factor year: 2025 — Official source; checked 2026-10-03. Publisher-reported Journal Impact Factor and year from Taylor & Francis About this journal information.
Source-backed journal facts
Topics in published research
Statistical Methods in Clinical Trials; Advanced Causal Inference Techniques; Health Systems, Economic Evaluations, Quality of Life; Optimal Experimental Design Methods; Statistical Methods and Bayesian Inference; Statistical Methods and Inference.
OpenAlex classifies topics from published works. These topics are not the publisher’s official aims and scope.
Source: OpenAlex source record. Retrieved 2026-10-03. Source record updated 2026-10-02. OpenAlex metrics are different from SCImago metrics and the Clarivate Journal Impact Factor.
Journal Metrics
Quartile, SJR and the listed SCImago H-index use the 2025 imported SCImago dataset. A quartile may vary by subject category. Values without a source or reporting year are unverified historical entries. Verify the current Journal Impact Factor with Clarivate or the publisher before using it.
Aims & Scope
The publisher’s official aims and scope have not yet been verified for this profile. Use the journal website to check subject fit and accepted article types before submitting.
Recent Research Articles
Latest publications matched automatically by ISSN.
Estimand and Causal Framework for Cardiovascular Trials with Non-Susceptible Fractions
Ayon Mukherjee, Atanu Bhattacharjee, Yongming Qu
2026-09-29 · DOI: 10.1080/19466315.2026.2722101Estimation After Selection in Seamless Phase II/III Drop-the-Losers Trials with Time-to-Event Endpoints
Mojammel Haque Sarkar, Mohd. Arshad, Masihuddin
2026-09-28 · DOI: 10.1080/19466315.2026.2739412Approximating Binary–Continuous Joint Distributions from Marginal Summaries: Application to Clinical Trial Simulation
Longwen Shang, Min Tsao, Zhaoze Liu, Xuekui Zhang et al.
2026-09-28 · DOI: 10.1080/19466315.2026.2719508Sample Size and Cost-Efficient Planning for Stepped-Wedge Cluster Randomized Trials with Varying Cluster Size
Medha P Sharma, Priyanka Majumder, Samiran Ghosh
2026-09-28 · DOI: 10.1080/19466315.2026.2738472Objective Bayes Factor Based Model Selection for Zero-Inflated Microbiome Count Data Under Jeffreys Prior
Paramahansa Pramanik, Arnab Kumar Maity
2026-09-25 · DOI: 10.1080/19466315.2026.2739408Investigating Heterogeneous Treatment Effects with a Latent Class Mixed Model in Average Bioequivalence
Eunjung Song, Bo-Hyung Kim, Woojoo Lee
2026-09-23 · DOI: 10.1080/19466315.2026.2723439Evaluating Time-Varying and Heterogeneous Efficacy of COVID-19 Antiviral Drugs
Ruoxi Lyu, Jialiang Jiang, Kwok Fai Lam, Yu Gu et al.
2026-09-16 · DOI: 10.1080/19466315.2026.2709381A Bayesian Model for Inferring Overall Survival Benefit from Progression-Free Survival in Oncology Trials
Steven Snapinn, Chunlei Ke, Srinand Nandakumar
2026-09-14 · DOI: 10.1080/19466315.2026.2733020Handling Missing Data in Ambulatory Blood Pressure Monitoring Safety Studies: A Simulation Study of Common Analytical Methods
Xutong Zhao, Runqiu Wang, Yu-Ting Weng, Dalong Huang et al.
2026-09-08 · DOI: 10.1080/19466315.2026.2723440Targeted Learning for Tilted Average Treatment Effects
Yixin Fang
2026-07-31 · DOI: 10.1080/19466315.2026.2703542Aligning Estimands to Strengthen the Credibility of Network Meta-Analysis: Implications for Indirect Treatment Comparisons
Xing Xing, Lifeng Lin, Jiayi Tong, Philip He et al.
2026-07-30 · DOI: 10.1080/19466315.2026.2703540Doubly Robust Estimation of Desirability of Outcome Ranking (DOOR) Probability with Application to MDRO Studies
Shiyu Shu, Toshimitsu Hamasaki, Scott Evans, Lauren Komarow et al.
2026-07-27 · DOI: 10.1080/19466315.2026.2697866A Bayesian Design with Efficient Backfilling and Expansion to Accelerate Phase I/II Trials Accommodating Late-Onset Competing Risk Outcomes
Yingjie Qiu, Mingyue Li
2026-07-27 · DOI: 10.1080/19466315.2026.2703535BOOST: An Adaptive Biomarker-Guided Simon Two-Stage Design with Explicit Control of Pooled and Subgroup Inference
Heling Tong, Haitao Pan, Hongyu Miao, Weichao Bao et al.
2026-07-27 · DOI: 10.1080/19466315.2026.2695044Extension and Application of the Partial Continual Reassessment Method to a Phase-IIa Dose-Finding Tuberculosis Trial with a Continuous Endpoint
Alessandra Serra, Thomas Jaki, Pavel Mozgunov
2026-07-06 · DOI: 10.1080/19466315.2026.2676642An Accelerated Failure Time Non-Mixture Cure Model for Long-Term Survival Data with Application to Brain Cancer
Zil-e- Huma, Muhammad Y. Danish
2026-07-06 · DOI: 10.1080/19466315.2026.2689364Harness the Power of Statistics, Data Science, and Digital Technology to Drive Patient-Focused Innovations Together - Special Issue for the 2024 Regulatory–Industry Statistics Workshop (RISW)
Jianchang Lin, Zhiheng Xu
2026-07-03 · DOI: 10.1080/19466315.2026.2673770Statistical Innovation for Integrated Evidence in Medical Product Development
Martin Posch, Ivan Chan
2026-07-03 · DOI: 10.1080/19466315.2026.2686055The Role of Post Intercurrent Event Data in the Estimation of Hypothetical Estimands in Clinical Trials
Jonathan W. Bartlett, Rhian M. Daniel
2026-07-01 · DOI: 10.1080/19466315.2026.2656257Comparability Assessment for Changes to Manufacturing Processes: Industry Recommendations on Bayesian Practices
Ji Young Kim, Stan Altan, Dwaine Banton, Tobias Eilert et al.
2026-06-30 · DOI: 10.1080/19466315.2026.2677711Reviews
Community Reviews
Version History
October 4, 2026 at 9:02 pm
October 2, 2026